These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20007955)

  • 21. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis.
    Fernández A; Velasco A; Prieto V; Canueto J; Alvarez A; Rodríguez A
    Am J Gastroenterol; 2008 Nov; 103(11):2951-2. PubMed ID: 19032482
    [No Abstract]   [Full Text] [Related]  

  • 22. Infliximab avoiding colectomy and maintaining remission in pediatric immunosuppressive-naïve ulcerative colitis achieving remarkable mucosal healing.
    Sciaudone G; Pellino G; Guadagni I; Selvaggi F
    Panminerva Med; 2010 Mar; 52(1):91-2. PubMed ID: 20228729
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyclosporin for severe ulcerative colitis: a user's guide.
    Kornbluth A; Present DH; Lichtiger S; Hanauer S
    Am J Gastroenterol; 1997 Sep; 92(9):1424-8. PubMed ID: 9317057
    [No Abstract]   [Full Text] [Related]  

  • 24. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
    Mocciaro F; Orlando A; Scimeca D; Cottone M
    Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data.
    Rossetti S; Actis GC; Fadda M; Rizzetto M; Palmo A
    Dig Liver Dis; 2004 Jun; 36(6):426-31. PubMed ID: 15248385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease].
    Quera R; Moreno M; Simian D; Ibáñez P; Lubascher J; Figueroa C; Flores L; Kronberg U; Pizarro G; Fluxá D
    Rev Med Chil; 2018 Nov; 146(11):1241-1251. PubMed ID: 30725037
    [No Abstract]   [Full Text] [Related]  

  • 29. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.
    Lees CW; Heys D; Ho GT; Noble CL; Shand AG; Mowat C; Boulton-Jones R; Williams A; Church N; Satsangi J; Arnott ID;
    Aliment Pharmacol Ther; 2007 Aug; 26(3):411-9. PubMed ID: 17635376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab for ulcerative colitis following liver transplantation.
    Lal S; Steinhart AH
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):277-80. PubMed ID: 17301656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug monitoring of biologics in inflammatory bowel disease.
    Eser A; Primas C; Reinisch W
    Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC; Prather CM
    Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England.
    Russo EA; Harris AW; Campbell S; Lindsay J; Hart A; Arebi N; Milestone A; Tsai HH; Walters J; Carpani M; Westaby D; Thillainayagam A; Bansi D; Ghosh S
    Aliment Pharmacol Ther; 2009 Feb; 29(3):308-14. PubMed ID: 19035973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?
    Ben-Horin S
    Gastroenterology; 2015 Jun; 148(7):1268-71. PubMed ID: 25921372
    [No Abstract]   [Full Text] [Related]  

  • 39. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.
    Ternant D; Mulleman D; Degenne D; Willot S; Guillaumin JM; Watier H; Goupille P; Paintaud G
    Ther Drug Monit; 2006 Apr; 28(2):169-74. PubMed ID: 16628126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis.
    Veerappan SG; O'Morain CA
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):830-2. PubMed ID: 19398919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.